SVF
Insufficient· Insufficient EvidenceNarrative Review

Advances in cell-based therapies for Peripheral arterial disease.

Ribeiro M.

Narrative Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, Immune Modulation, published in Tissue Cell (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Tissue Cell (2026)
Country
Scotland
Reported sample size
—
PMID
41806630
DOI
10.1016/j.tice.2026.103417

Abstract (original English)

Peripheral arterial disease (PAD) affects more than 230 million individuals worldwide, with critical limb ischemia (CLI) representing its most severe and life-threatening stage. Despite advances in pharmacological management and revascularization techniques, up to 40% of patients with CLI remain unsuitable for conventional interventions, underscoring the need for alternative therapeutic strategies. Cell-based therapies have emerged as a potential regenerative approach aimed at restoring microvascular perfusion, enhancing wound healing, and preventing limb loss. This narrative review critically examines the clinical translation of cell therapies for vascular regeneration, with a focus on CLI and diabetic foot ulcers. We compare the efficacy, safety, and translational maturity of major cell sources, including autologous bone marrow- and adipose-derived mesenchymal stromal cells, umbilical cord-derived cells, fetal progenitor cells, and induced pluripotent stem cell-based platforms. Current clinical evidence suggests heterogeneous efficacy across cell types, with overall favorable safety profiles but inconsistent functional outcomes. Increasing evidence indicates that paracrine signaling, immunomodulation, and angiogenic factor secretion play a more decisive role in therapeutic benefit than direct cellular engraftment or differentiation. Major barriers to clinical adoption include

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansPeripheral Arterial DiseaseCell- and Tissue-Based TherapyAnimalsIschemia
Ankle & FootDiabetic FootPeripheral Artery DiseaseChronic WoundImmune Modulation
View on PubMedDOI

Related research